Project Description
Follow-On Offering
Common Stock
.
$115,000,000
Financial Advisor
February 2021
EyePoint PharmaceuticalsStephen DeLorme2022-12-19T12:34:33-05:00
EyePoint PharmaceuticalsStephen DeLorme2022-12-19T12:34:33-05:00
EyePoint PharmaceuticalsStephen DeLorme2022-12-19T12:34:33-05:00